
-
Trump threatens allies Japan, South Korea with 25% tariffs
-
Relentless Spain thump Belgium to close in on Euro 2025 quarters
-
Wimbledon changes line-calling system after embarrassing blunder
-
France backs returning colonial-era 'talking drum' to I.Coast
-
King hails 'spirit of unity' as Britain remembers 7/7 attacks
-
US measles epidemic its worst of 21st century
-
Djokovic survives scare to reach Wimbledon quarters, Sinner in action
-
Looted art: the battle for looted treasures
-
Trump slaps allies Japan, South Korea with 25% tariffs
-
Belgian Merlier wins crash-marred Tour de France dash to Dunkirk
-
Celebs light up Schiaparelli to open Paris Haute Couture Week
-
Youth camp confirms 27 dead as Texas flood toll nears 90
-
Respect for Lara stops Mulder short of world Test record
-
Mexico president slams xenophobia after anti-gentrification protest
-
Djokovic stays on track for Wimbledon glory under Federer gaze
-
Belgian Merlier wins crash-marred Tour de France stage
-
Djokovic battles back against De Minaur to stay on track for Wimbledon glory
-
Israel, Hamas hold indirect talks ahead of Netanyahu-Trump meet
-
Trump steps up pressure for deals as US tariff deadline nears
-
Iran president says Israel attempted to assassinate him
-
Russia says minister fired by Putin killed himself
-
Ex-All Black Nonu extends Toulon deal, aged 43
-
Stocks diverge as US tariff deadline looms
-
French court dismisses government Covid response probe
-
Children's camp confirms 27 dead, with Texas flood toll over 80
-
BRICS' criticism brings Trump 10% tariff threat
-
Houses made from rice: Kyrgyzstan's eco-friendly revolution
-
Croatia govt lashed over 'disgraceful neo-fascist Woodstock'
-
Victims of London 7/7 attacks remembered as king hails 'spirit of unity'
-
Poland starts border checks with Germany in anti-migrant clampdown
-
Wiaan Mulder: slow ascent to Test cricket's batting heights
-
England coach McCullum says paceman Archer 'ready to go' against India
-
Djokovic, Sinner on Wimbledon collision course
-
Vaughan says Crawley 'lucky' to have so many England caps
-
Russian forces claim first foothold in new Ukraine region
-
US envoy says satisfied with Lebanese response on disarming of Hezbollah
-
European stocks, dollar firm as US tariff deadline looms
-
Wimbledon blames 'human error' for embarrassing line-calling glitch
-
Three things learned from British Grand Prix
-
NGOs laud tougher Malaysia plastic trash import laws
-
Mulder makes highest South Africa Test score
-
UK marks London 7/7 attacks as king hails 'spirit of unity'
-
Apple appeals 500-mn-euro EU fine
-
Crowds celebrate Nepal ex-king's birthday in show of support
-
Bali flights nixed after huge Indonesia volcano eruption
-
Hamas, Israel resume talks as Netanyahu set to meet Trump
-
Hong Kong fans queue for opening of Cristiano Ronaldo exhibition
-
Itoje back as Lions take no chances against ACT Brumbies
-
Stock markets struggle as Trump's tariff deadline looms
-
Nearly 450,000 Afghans left Iran since June 1: IOM

Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
L.Mason--AMWN